Valeant Pharma (VRX) Reports Q3 EPS of $2.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharmaceuticals (VRX) PT, Estimates Raised at Jefferies on Strong Q3
October 21, 2014 8:00 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and boosted his price target on Valeant Pharmaceuticals (NYSE: VRX) to $149.00 (from $141.00) following strong Q3 results.
Steinberg commented, "Valeant reported a strong Q3 as expected. While revs of $2.06B were slightly dampened due... More
Valeant Pharma (VRX) Posts Strong Q3 Results, Bumps Outlook Higher; Aegis Capital Maintains at 'Buy'
October 20, 2014 9:55 AM EDTAegis Capital affirms its Buy rating and $180 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q3 results and guidance update.
Analyst Ram Selvaraju commented, This morning, Valeant reported third quarter 2014 financial results. The firm delivered cash EPS of $2.11 per share vs. our projection of... More
